DVT-PE in cancer: Oral anticoagulant edoxaban non-inferior to enoxaparin
www.pulmccm.org
Most patients with cancer-associated deep venous thrombosis (DVT) or pulmonary embolism (PE) in the U.S. are treated indefinitely with subcutaneous injections of low-molecular weight heparin (LMWH), like enoxaparin. LMWH has been shown to be better than warfarin at preventing DVT/PE in cancer patients, with similar rates of bleeding.
DVT-PE in cancer: Oral anticoagulant edoxaban non-inferior to enoxaparin
DVT-PE in cancer: Oral anticoagulant edoxaban…
DVT-PE in cancer: Oral anticoagulant edoxaban non-inferior to enoxaparin
Most patients with cancer-associated deep venous thrombosis (DVT) or pulmonary embolism (PE) in the U.S. are treated indefinitely with subcutaneous injections of low-molecular weight heparin (LMWH), like enoxaparin. LMWH has been shown to be better than warfarin at preventing DVT/PE in cancer patients, with similar rates of bleeding.
Comments on this post are for paid subscribers